New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims - The New York Times

A late-stage trial was halted after strong early results, according to the company, but the data have not yet been published or peer-reviewed.

The drug was granted so-called fast-track status by the Food and Drug Administration in January, Dr. Steiner said. The designation is intended to prompt faster development and review of new treatment… [+1819 chars]

full article...